Valuation: HighTide Therapeutics, Inc.

Market Cap 127.24Cr 147.4Cr 19Cr 16Cr 15Cr 14Cr 26Cr 1.8TCr 27Cr 182.26Cr 71Cr 890.66Cr 71Cr 69Cr 3.08TCr P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 90Cr 103.85Cr 13Cr 12Cr 11Cr 9.95Cr 19Cr 1.27TCr 19Cr 128.4Cr 50Cr 627.49Cr 50Cr 49Cr 2.17TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.17%
Yield 2024 *
-
Yield 2025 -
1 day-3.10%
1 week-3.10%
Current month-6.72%
1 month-10.39%
3 months-30.94%
6 months-6.72%
Current year-15.25%
1 week 2.47
Extreme 2.47
2.94
1 month 2.32
Extreme 2.32
3.01
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Director/Board Member 68 30/11/2020
Director/Board Member 61 -
Chairman 56 -
Date Insider Type Main position Quantity % Market Cap.
30/04/26 Other

Director

18,00,000 0.3151%
01/04/26 Other

Chief Executive Officer

83,25,618 1.4572%
01/04/25 Other

Chief Executive Officer

39,60,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
-3.10%-3.10%-31.32% - 19Cr
-0.36%+1.42%+49.53%+68.32% 5.5TCr
-1.32%-2.71%+34.27%+77.57% 5.42TCr
+1.49%+0.13%-18.03%-13.94% 2.34TCr
-0.57%-4.13%+2.34%+387.73% 2.26TCr
+2.07%+1.39%+17.20%-10.70% 2.02TCr
-0.51%-0.50%+29.62%-31.77% 1.79TCr
-2.14%-3.75%+26.23%+558.64% 1.55TCr
-6.69%-5.11%+169.13%+304.89% 1.42TCr
+1.25%+0.69%+27.30%+184.69% 1.42TCr
Average -0.99%-0.79%+30.63%+169.49% 2.37TCr
Weighted average by Cap. -0.62%-0.52%+34.89%+131.64%

Financials

2024 2025
Net sales - -
Net income -38Cr -44Cr -5.64Cr -4.95Cr -4.61Cr -4.24Cr -7.95Cr -538.86Cr -8.08Cr -55Cr -21Cr -267.24Cr -21Cr -21Cr -923.32Cr -24Cr -28Cr -3.62Cr -3.18Cr -2.96Cr -2.72Cr -5.1Cr -345.75Cr -5.19Cr -35Cr -14Cr -171.47Cr -14Cr -13Cr -592.43Cr
Net Debt -41Cr -48Cr -6.1Cr -5.35Cr -4.98Cr -4.58Cr -8.59Cr -582.63Cr -8.74Cr -59Cr -23Cr -288.94Cr -23Cr -22Cr -998.31Cr -38Cr -44Cr -5.55Cr -4.87Cr -4.54Cr -4.17Cr -7.83Cr -530.64Cr -7.96Cr -54Cr -21Cr -263.16Cr -21Cr -20Cr -909.23Cr
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51
Date Price Change Volume
29/26/29 HK$2.500 -3.10% 1,32,616
28/26/28 HK$2.580 -2.64% 1,16,000
27/26/27 HK$2.650 0.00% 25,000
24/26/24 HK$2.650 -1.12% 67,000
23/26/23 HK$2.680 +3.88% 1,85,500

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock